Presence of Serum Antinuclear Antibodies Does Not Impact Long-Term Outcomes in Nonalcoholic Fatty Liver Disease. (August 2020)

• Record Type: Journal Article
• Authors: Younes, Ramy; Govaere, Olivier; Petta, Salvatore; Miele, Luca; Tiniakos, Dina; Burt, Alastair; David, Ezio; Vecchio, Fabio M.; Maggioni, Marco; Cabibi, Daniela; Fracanzani, Anna L.; Rosso, Chiara; Blanco, Maria J. Garcia; Armandi, Angelo; Caviglia, Gian Paolo; Zaki, Marco Y. W.; Liguori, Antonio; Francione, Paolo; Pennisi, Grazia; Grieco, Antonio; Valenti, Luca; Anstee, Quentin M.; Bugianesi, Elisabetta
• Is Part Of: American journal of gastroenterology. Volume 115:Number 8(2020)
• Publication Date: 2020-08
• Subjects: Stomach -- Diseases -- Periodicals; Intestines -- Diseases -- Periodicals; Gastroenterology -- Periodicals; Gastrointestinal Diseases -- Periodicals; Electronic journals; Periodicals; 616.33
• DOI: 10.14309/ajg.0000000000000676
• Languages: English
• ISSNs: 0002-9270

Abstract

Abstract : INTRODUCTION: We investigated the longitudinal impact of antinuclear antibody (ANA) on clinical outcomes and survival in nonalcoholic fatty liver disease (NAFLD). METHODS: ANA were found in 16.9% of 923 biopsy-proven NAFLD patients, but none of them had histologic autoimmune hepatitis (AIH) or developed AIH after a mean follow-up of 106±50 months. RESULTS: Although ANA-positive cases had a higher prevalence of nonalcoholic steatohepatitis at baseline, the occurrence of liver-related events, hepatocellula carcinoma, cardiovascular events, extrahepatic malignancy, and overall survival were similar to ANA-negative. DISCUSSION: Once AIH has been ruled out, the long-term outcomes and survival are unaffected by the presence of ANA in patients with NAFLD.